文献速递乳腺癌放疗放疗物理与技术

新辅助磁共振引导单次消融剂量部分乳腺照射后的肿瘤反应

Tumor Response After Neoadjuvant Magnetic Resonance Guided Single Ablative Dose Partial Breast Irradiation.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2019-12-05

病理完全缓解(pCR)率为 42%(95%CI 26%–59%),放射性完全缓解 15 例中 10 例 pCR(阳性预测值 67%,95%CI 39%–87%);中位随访 21 个月未见局部复发,毒性可接受,患者报告结局与美容效果无恶化。

要点

  • NA-PBI 后 pCR 率为 42%(95%CI 26%–59%),提示该方案有诱导病理缓解的潜力。
  • MRI 放射性完全缓解对 pCR 的阳性预测值为 67%(95%CI 39%–87%),预测准确性有限。
  • 中位随访 21 个月无局部复发,全部患者出现 1 级纤维化,2 级和 3 级毒性分别为 31% 和 3%。

核心结论

  • MR 引导新辅助单次消融剂量部分乳腺照射可在相当比例低危乳腺癌患者中诱导 pCR,毒性可接受。
  • 该治疗或可作为标准术后放疗的可行替代,若能在选定低危患者中准确预测 pCR,甚至可能推迟或免于手术。

研究设计与样本

  • 单臂前瞻性 trial,纳入单灶、非小叶型、最大径 20 mm(年龄 50–70 岁)或 30 mm(年龄≥70 岁)且前哨淋巴结阴性的女性乳腺癌患者。
  • 患者接受单次消融剂量 NA-PBI,6–8 个月后行保乳手术;GTV 处方剂量 20 Gy,CTV(GTV 加 20 mm 边界)处方剂量 15 Gy。
  • 主要终点为病理完全缓解(pCR),次要终点包括影像学反应、毒性、患者报告结局和美容效果。

主要发现

  • 影像学完全缓解 15 例,其中 10 例 pCR(阳性预测值 67%;95%CI 39%–87%)。
  • 中位随访 21 个月(范围 12–41),全部患者出现治疗侧乳腺 1 级纤维化,31% 出现暂时性 2 级毒性,3% 出现暂时性 3 级毒性。
  • 未见局部复发,患者报告结局与美容效果未见恶化。

关键数值与推荐

  • GTV 处方剂量 20 Gy,CTV(GTV 加 20 mm 边界)处方剂量 15 Gy,单次照射。
  • 影像学完全缓解对 pCR 的阳性预测值为 67%(95%CI 39%–87%)。
  • 毒性按 Common Terminology Criteria for Adverse Events 分级,全部患者为 1 级纤维化,2 级和 3 级暂时性毒性分别为 31% 和 3%。

临床怎么用

  • 对选定低危乳腺癌患者,MR 引导新辅助单次部分乳腺照射后 6–8 个月手术的方案可行,毒性可接受。
  • 影像学完全缓解不能可靠等同于 pCR,阳性预测值 67%,不宜单独据此决定推迟或省略手术。
  • 该策略仍需进一步验证 pCR 的准确预测手段,方可考虑用于推迟或免于手术。

局限性

  • pCR 率及影像学阳性预测值的 95%CI 较宽,结论需更大样本验证。
  • 随访时间不足以评估长期局部控制、晚期毒性和美容结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess the pathologic and radiologic response in patients with low-risk breast cancer treated with magnetic resonance (MR) guided neoadjuvant partial breast irradiation (NA-PBI) and to evaluate toxicity and patient-reported outcomes (PROs). METHODS AND MATERIALS: For this single-arm prospective trial, women with unifocal, non-lobular tumors with a maximum diameter of 20 mm (age, 50-70 years) or 30 mm (age, ≥70 years) and tumor-negative sentinel node(s) were eligible. Patients were treated with a single ablative dose of NA-PBI followed by breast-conserving surgery after an interval of 6 to 8 months. Target volumes were defined on radiation therapy planning computed tomography scan and additional magnetic resonance imaging. Prescribed doses to gross tumor volume and clinical target volume (gross tumor volume plus 20 mm margin) were 20 Gy and 15 Gy, respectively. Primary outcome was pathologic complete response (pCR). Secondary outcomes were radiologic response (on magnetic resonance imaging), toxicity (Common Terminology Criteria for Adverse Events), PROs (European Organisation for Research and Treatment of Cancer QLQ-BR23, Hospital Anxiety and Depression Scale), and cosmesis (assessed by patient, radiation oncologist, and BCCT.core software). RESULTS: Thirty-six patients were treated with NA-PBI, and pCR was reported in 15 patients (42%; 95% confidence interval, 26%-59%). Radiologic complete response was observed in 15 patients, 10 of whom had pCR (positive predictive value, 67%; 95% confidence interval, 39%-87%). After a median follow-up of 21 months (range, 12-41), all patients experienced grade 1 fibrosis in the treated breast volume. Transient grade 2 and 3 toxicity was observed in 31% and 3% of patients, respectively. Local recurrences were absent. No deterioration in PROs or cosmetic results was observed. CONCLUSIONS: NA-PBI has the potential to induce pCR in a substantial proportion of patients, with acceptable toxicity. This treatment seems a feasible alternative to standard postoperative irradiation and could even result in postponement or omission of surgery if pCR can be accurately predicted in selected low-risk patients.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Vasmel JE, Charaghvandi RK, Houweling AC, et al. Tumor Response After Neoadjuvant Magnetic Resonance Guided Single Ablative Dose Partial Breast Irradiation. Int J Radiat Oncol Biol Phys. 2019. PMID: 31812720. doi:10.1016/j.ijrobp.2019.11.406

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。